John Duncan Higgons, Director at Jounce Therapeutics, Inc. (JNCE), sold 1,700 shares at $11.11 ($20K) on 2021-01-21, disclosed to the SEC on 2021-01-22.
Scheduled sale ($20k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.00 | 1,500 | $18K | 89.0% |
| 2 | $11.11 | 200 | $2K | 11.0% |
| Total | $11.90 avg | 1,700 | $20K | 100% |
| Filing → |
| JNCE | SELL | 2021-02-18 | $2K | — | Filing → |
| JNCE | SELL | 2020-01-08 | $12K | — | Filing → |
| JNCE | BUY | 2017-02-02 | $107K | — | Filing → |